BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1400
- Registration Number
- NCT05666518
- Locations
- 🇯🇵
Japanese registries, Multiple Locations, Many Locations, Japan
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
- Conditions
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 205
- Registration Number
- NCT05658458
- Locations
- 🇮🇳
Max Super Speciality Hospital, Saket, New Delhi, Delhi, India
🇮🇳Safdarjung Hospital, New Delhi, Delhi, India
🇮🇳Vijan Cardiac & Critical Care Centre, Nashik, Maharashtra, India
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 77
- Registration Number
- NCT05656911
- Locations
- 🇵🇱
Santa Sp. z o.o., Lodz, Poland
🇫🇷Clinique Bezannes, Bezannes, France
🇩🇪Charité - Universitätsmedizin Berlin, Berlin, Germany
An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
- Conditions
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT05643560
- Locations
- 🇮🇹
Many Locations, Multiple Locations, Italy
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14830
- Registration Number
- NCT05643573
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy Sciences, Ningbo, Zhejiang, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University (West), Beijing, China
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17847
- Registration Number
- NCT05640180
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 284
- Registration Number
- NCT05614102
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸UF Health Cancer Center, Gainesville, Florida, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT05599997
- Locations
- 🇩🇪
APEX GmbH, München, Bayern, Germany
🇩🇪CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4103
- Registration Number
- NCT05594147
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 473
- Registration Number
- NCT05587296
- Locations
- 🇮🇱
Assuta Ashdod Public Hospital (R.A), Ashdod, Israel
🇮🇹IRCCS Ospedale Policlinico San Martino - Clinica ostetrica e ginecologica, Genova, Liguria, Italy
🇦🇹Medical University of Graz | Division of Gynecology and Obstetrics, Graz, Steiermark, Austria